These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8882320)

  • 21. An overview of vaccine vectors.
    Dorner F
    Dev Biol Stand; 1995; 84():23-32. PubMed ID: 7796959
    [No Abstract]   [Full Text] [Related]  

  • 22. The impact of vaccines and the future of genetically modified poxvirus vaccines for poultry.
    Tripathy DN
    Anim Health Res Rev; 2004 Dec; 5(2):263-6. PubMed ID: 15984336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Japanese encephalitis vaccines: moving away from the mouse brain.
    Zanin MP; Webster DE; Martin JL; Wesselingh SL
    Expert Rev Vaccines; 2003 Jun; 2(3):407-16. PubMed ID: 12903806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a non-immunising, paraspecific vaccine from attenuated pox viruses: a new type of vaccine.
    Mayr A
    New Microbiol; 2003 Jan; 26(1):7-12. PubMed ID: 12578306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
    Taylor J; Paoletti E
    Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influenza vaccines.
    Clements ML
    Biotechnology; 1992; 20():129-50. PubMed ID: 1600379
    [No Abstract]   [Full Text] [Related]  

  • 27. Limited infection upon human exposure to a recombinant raccoon pox vaccine vector.
    Rocke TE; Dein FJ; Fuchsberger M; Fox BC; Stinchcomb DT; Osorio JE
    Vaccine; 2004 Jul; 22(21-22):2757-60. PubMed ID: 15246608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reflections on the early development of poxvirus vectors.
    Moss B
    Vaccine; 2013 Sep; 31(39):4220-2. PubMed ID: 23583893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
    Didierlaurent A; Ramirez JC; Gherardi M; Zimmerli SC; Graf M; Orbea HA; Pantaleo G; Wagner R; Esteban M; Kraehenbuhl JP; Sirard JC
    Vaccine; 2004 Sep; 22(25-26):3395-403. PubMed ID: 15308364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adult T-cell leukemia: future prophylaxis and immunotherapy.
    Kannagi M; Harashima N; Kurihara K; Utsunomiya A; Tanosaki R; Masuda M
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):369-76. PubMed ID: 15161436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innate immune recognition of poxviral vaccine vectors.
    Lousberg EL; Diener KR; Brown MP; Hayball JD
    Expert Rev Vaccines; 2011 Oct; 10(10):1435-49. PubMed ID: 21988308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poxviruses as vaccine vectors.
    Pastoret PP; Vanderplasschen A
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):343-55. PubMed ID: 12818621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help.
    Estcourt MJ; McMichael AJ; Hanke T
    Eur J Immunol; 2005 Dec; 35(12):3460-7. PubMed ID: 16245361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antiviral vaccines].
    Girard M
    Med Trop (Mars); 1999; 59(4 Pt 2):522-6. PubMed ID: 10901858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA plasmid based vaccination against the oncogenic human T cell leukemia virus type 1.
    Agadjanyan MG; Wang B; Nyland SB; Weiner DB; Ugen KE
    Curr Top Microbiol Immunol; 1998; 226():175-92. PubMed ID: 9479842
    [No Abstract]   [Full Text] [Related]  

  • 36. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
    Casimiro DR; Bett AJ; Fu TM; Davies ME; Tang A; Wilson KA; Chen M; Long R; McKelvey T; Chastain M; Gurunathan S; Tartaglia J; Emini EA; Shiver J
    J Virol; 2004 Oct; 78(20):11434-8. PubMed ID: 15452269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Preliminary study of the safety and immunogenicity of the attenuated VD47/25 strain of camelpoxvirus].
    Nguyen-Ba-Vy ; Guerre L; Saint-Martin G
    Rev Elev Med Vet Pays Trop; 1996; 49(3):189-94. PubMed ID: 9091989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia.
    Kozako T; Fukada K; Hirata S; White Y; Harao M; Nishimura Y; Kino Y; Soeda S; Shimeno H; Lemonnier F; Sonoda S; Arima N
    Mol Immunol; 2009 Dec; 47(2-3):606-13. PubMed ID: 19889459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences between extracellular and intracellular forms of poxvirus and their implications.
    Boulter EA; Appleyard G
    Prog Med Virol; 1973; 16():86-108. PubMed ID: 4356899
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus).
    Kazanji M; Tartaglia J; Franchini G; de Thoisy B; Talarmin A; Contamin H; Gessain A; de Thé G
    J Virol; 2001 Jul; 75(13):5939-48. PubMed ID: 11390595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.